{"commentary":{"count":22,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":10,"x_thread":8,"podcast":4},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05623020\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"MagnetisMM-6","nct_id":"NCT05623020","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=magnetismm-6-nct05623020. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"MagnetisMM-6","arms":[{"description":null,"label":"Part 1, Dose Level 1: Elranatamab + Daratumumab + Lenalidomide","type":"EXPERIMENTAL"},{"description":null,"label":"Part 1, Multiple Dose Levels, Elranatamab + Daratumumab + Lenalidomide","type":"EXPERIMENTAL"},{"description":null,"label":"Part 2 Randomized Arm A: Elranatamab + Daratumumab + Lenalidomide","type":"EXPERIMENTAL"},{"description":null,"label":"Part 2 Randomized Arm B: Daratumumab + Bortezomib + Lenalidomide + Dexamethasone","type":"ACTIVE_COMPARATOR"},{"description":null,"label":"Part 1: Elranatamab + Lenalidomide","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2033-10-03","type":"ESTIMATED"},"conditions":["Multiple Myeloma"],"enrollment":{"count":1060,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Elranatamab","type":"DRUG"},{"name":"Daratumumab","type":"DRUG"},{"name":"Lenalidomide","type":"DRUG"},{"name":"Dexamethasone","type":"DRUG"},{"name":"Bortezomib","type":"DRUG"}],"last_update":"2026-09-25","lead_sponsor":"Pfizer","official_title":"AN OPEN-LABEL, 2-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) + DARATUMUMAB + LENALIDOMIDE VERSUS DARATUMUMAB + BORTEZOMIB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANT-INELIGIBLE PARTICIPANTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2030-10-18","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Part 1 Dose Limiting Toxicity","timeFrame":"From the first dose of elranatamab/first full dose in combination with EDR until 28 days (+/- visit window) from the first administration of elranatamab with daratumumab and lenalidomide"},{"measure":"Part 2: Progression free survival per IMWG","timeFrame":"From randomization up to 97 months."},{"measure":"Part 2: Minimal Residual Disease negative CR rate","timeFrame":"At 12 months after randomization"}],"references":[],"start_date":{"date":"2022-11-10","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant","url":"https://clinicaltrials.gov/study/NCT05623020"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/magnetismm-6-nct05623020"}